Publicaciones (27) Publicaciones de MARÍA CALLEJO ARRANZ

2023

  1. Corrigendum: Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model (Frontiers in Pharmacology, (2023), 14, (1021535), 10.3389/fphar.2023.1021535)

    Frontiers in Pharmacology

  2. Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model

    Frontiers in Pharmacology, Vol. 14

  3. Survivin inhibition with YM155 ameliorates experimental pulmonary arterial hypertension

    Frontiers in Pharmacology, Vol. 14

2022

  1. Cardiac and Pulmonary Vascular Dysfunction in Vitamin D-Deficient Bmpr2-Mutant Rats

    American journal of respiratory cell and molecular biology

2021

  1. Oxygen-sensitivity and pulmonary selectivity of vasodilators as potential drugs for pulmonary hypertension

    Antioxidants, Vol. 10, Núm. 2, pp. 1-14

  2. Restoration of vitamin d levels improves endothelial function and increases task-like k+ currents in pulmonary arterial hypertension associated with vitamin d deficiency

    Biomolecules, Vol. 11, Núm. 6

  3. Vitamin D deficiency, a potential cause for insufficient response to sildenafil in pulmonary arterial hypertension

    European Respiratory Journal

2020

  1. Impact of nutrition on pulmonary arterial hypertension

    Nutrients, Vol. 12, Núm. 1

  2. Total, bioavailable, and free vitamin D levels and their prognostic value in pulmonary arterial hypertension

    Journal of Clinical Medicine, Vol. 9, Núm. 2

  3. Uncovered Contribution of Kv7 Channels to Pulmonary Vascular Tone in Pulmonary Arterial Hypertension

    Hypertension, Vol. 76, Núm. 4, pp. 1134-1146

  4. Vitamin D deficiency downregulates TASK-1 channels and induces pulmonary vascular dysfunction

    American Journal of Physiology - Lung Cellular and Molecular Physiology, Vol. 319, Núm. 4, pp. L627-L640

2019

  1. Activation of Kv7 channels as a novel mechanism for NO/cGMP-induced pulmonary vasodilation

    British Journal of Pharmacology, Vol. 176, Núm. 13, pp. 2131-2145

  2. Elevated pulmonary arterial pressure in Zucker diabetic fatty rats

    PLoS ONE, Vol. 14, Núm. 1

  3. Impact of vitamin D deficit on the rat gut microbiome

    Nutrients, Vol. 11, Núm. 11

  4. MicroRNAs in respiratory diseases

    Nucleic Acid Nanotheranostics: Biomedical Applications (Elsevier), pp. 89-131

  5. miR-1 induces endothelial dysfunction in rat pulmonary arteries

    Journal of Physiology and Biochemistry, Vol. 75, Núm. 4, pp. 519-529

  6. miR-1 is increased in pulmonary hypertension and downregulates Kv1.5 channels in rat pulmonary arteries

    Journal of Physiology, Vol. 597, Núm. 4, pp. 1185-1197

2018

  1. HIV transgene expression impairs K+ channel function in the pulmonary vasculature

    American Journal of Physiology - Lung Cellular and Molecular Physiology, Vol. 315, Núm. 5, pp. L711-L723

  2. Pulmonary Arterial Hypertension Affects the Rat Gut Microbiome

    Scientific Reports, Vol. 8, Núm. 1

  3. Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation/ perfusion matching

    PLoS ONE, Vol. 13, Núm. 1